Back to Search Start Over

Protective role of complement factor H against the development of preeclampsia.

Authors :
Yasmin H
Agostinis C
Toffoli M
Roy T
Pegoraro S
Balduit A
Zito G
Di Simone N
Ricci G
Madan T
Kishore U
Bulla R
Source :
Frontiers in immunology [Front Immunol] 2024 Feb 23; Vol. 15, pp. 1351898. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
Publication Year :
2024

Abstract

Pregnancy is an immunologically regulated, complex process. A tightly controlled complement system plays a crucial role in the successful establishment of pregnancy and parturition. Complement inhibitors at the feto-maternal interface are likely to prevent inappropriate complement activation to protect the fetus. In the present study, we aimed to understand the role of Factor H (FH), a negative regulator of complement activation, in normal pregnancy and in a model of pathological pregnancy, i.e. preeclampsia (PE). The distribution and expression of FH was investigated in placental tissues, various placental cells, and in the sera of healthy (CTRL) or PE pregnant women via immunohistochemistry, RT-qPCR, ELISA, and Western blot. Our results showed a differential expression of FH among the placental cell types, decidual stromal cells (DSCs), decidual endothelial cells (DECs), and extravillous trophoblasts (EVTs). Interestingly, FH was found to be considerably less expressed in the placental tissues of PE patients compared to normal placental tissue both at mRNA and protein levels. Similar results were obtained by measuring circulating FH levels in the sera of third trimester CTRL and PE mothers. Syncytiotrophoblast microvesicles, isolated from the placental tissues of PE and CTRL women, downregulated FH expression by DECs. The present study appears to suggest that FH is ubiquitously present in the normal placenta and plays a homeostatic role during pregnancy.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 Yasmin, Agostinis, Toffoli, Roy, Pegoraro, Balduit, Zito, Di Simone, Ricci, Madan, Kishore and Bulla.)

Details

Language :
English
ISSN :
1664-3224
Volume :
15
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
38464530
Full Text :
https://doi.org/10.3389/fimmu.2024.1351898